Gary Remington focuses on Schizophrenia, Psychiatry, Psychosis, Antipsychotic and Internal medicine. His Schizophrenia study frequently draws connections to adjacent fields such as Psychopathology. His Psychiatry study typically links adjacent topics like Clinical psychology.
His study looks at the intersection of Psychosis and topics like Neuroscience with Anticipation. His Antipsychotic research incorporates themes from Risperidone, Dopamine receptor D2, Clinical trial and Polypharmacy. His biological study spans a wide range of topics, including Endocrinology and Atypical antipsychotic.
His primary areas of investigation include Schizophrenia, Psychiatry, Antipsychotic, Internal medicine and Clinical psychology. His study in Schizophrenia is interdisciplinary in nature, drawing from both Psychosis, Psychopathology and Cognition. Much of his study explores Psychiatry relationship to Quality of life.
His Antipsychotic research is multidisciplinary, incorporating elements of Tardive dyskinesia, Dopamine receptor D2, Olanzapine, Risperidone and Pharmacology. His studies deal with areas such as Anesthesia, Endocrinology and Atypical antipsychotic as well as Internal medicine. He has included themes like Life satisfaction and Depression in his Clinical psychology study.
His scientific interests lie mostly in Schizophrenia, Internal medicine, Antipsychotic, Endocrinology and Clozapine. His Schizophrenia research is multidisciplinary, incorporating perspectives in Psychosis, Cognition and Clinical psychology. His Psychosis study is related to the wider topic of Psychiatry.
His studies in Internal medicine integrate themes in fields like Oncology and Cardiology. His work in Antipsychotic covers topics such as Pharmacogenetics which are related to areas like Bioinformatics and Allele. The concepts of his Clozapine study are interwoven with issues in Working memory, Psychopathology, Muscarinic acetylcholine receptor and Acetylcholine receptor.
The scientist’s investigation covers issues in Schizophrenia, Antipsychotic, Internal medicine, Cognition and Psychosis. His Schizophrenia research integrates issues from Meta-analysis and Clinical psychology. His work carried out in the field of Antipsychotic brings together such families of science as Gold standard, Randomized controlled trial, Adverse effect and Tardive dyskinesia.
His work is dedicated to discovering how Internal medicine, Endocrinology are connected with Drug, In vivo and Prefrontal cortex and other disciplines. His work in Cognition tackles topics such as Amotivation which are related to areas like Psychiatry, Need for achievement, Brain size and Stepwise regression. The Psychosis study combines topics in areas such as First episode and Body mass index, Waist, Waist–hip ratio.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia
Shitij Kapur;Robert Zipursky;Corey Jones;Gary Remington.
American Journal of Psychiatry (2000)
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Guy Chouinard;Barry Jones;Gary Remington;David Bloom.
Journal of Clinical Psychopharmacology (1993)
Serotonin-dopamine interaction and its relevance to schizophrenia
Shitij Kapur;Gary Remington.
American Journal of Psychiatry (1996)
Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Shitij Kapur;Robert B. Zipursky;Gary Remington.
American Journal of Psychiatry (1999)
Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics
Claire H. Li;Robert E. Stratford;Nieves Velez de Mendizabal;Thomas I.F.H. Cremers.
Journal of Translational Medicine (2014)
Negative Symptoms in Schizophrenia: Avolition and Occam's Razor
George Foussias;George Foussias;Gary Remington;Gary Remington.
Schizophrenia Bulletin (2010)
A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
Shitij Kapur;Robert Zipursky;Corey Jones;C. S. Shammi.
Archives of General Psychiatry (2000)
Direct Activation of the Ventral Striatum in Anticipation of Aversive Stimuli
Jimmy Jensen;Anthony R McIntosh;Adrian P Crawley;David J Mikulis.
5-HT2 and D2 Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Shitij Kapur;Robert B. Zipursky;Gary Remington;Corey Jones.
American Journal of Psychiatry (1998)
Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient
Shitij Kapur;Shitij Kapur;Gary Remington.
Biological Psychiatry (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: